A viral threat can arise suddenly and quickly turn into a major epidemic or pandemic. In such a case, it is necessary to develop effective means of therapy and prevention in a short time. Vaccine development takes decades, and the use of antiviral compounds is often ineffective and unsafe. A quick response may be the use of convalescent plasma, but a number of difficulties associated with it forced researchers to switch to the development of safer and more effective drugs based on monoclonal antibodies (mAbs). In order to provide protection, such drugs must have a key characteristic-neutralizing properties, i.e., the ability to block viral infection. Currently, there are several approaches to produce mAbs in the researchers' toolkit, however, none of them may serve as a gold standard. Each approach has its own advantages and disadvantages. The choice of the method depends both on the characteristics of the virus and on time constraints and technical challenges. This review provides a comparative analysis of modern methods to produce neutralizing mAbs and describes current trends in the design of antibodies for therapy and prevention of viral diseases.
Keywords: B-cell sorting; display technology; hybridoma technology; monoclonal antibodies; viral infections.
© Pleiades Publishing, Ltd. 2022, ISSN 1068-1620, Russian Journal of Bioorganic Chemistry, 2022, Vol. 48, No. 2, pp. 256–272. © Pleiades Publishing, Ltd., 2022.Russian Text © The Author(s), 2022, published in Bioorganicheskaya Khimiya, 2022, Vol. 48, No. 3, pp. 279–295.